This morning, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced positive top line results from an open label exploratory CBD-based Phase 2 clinical trial of the company's "FAB-C" drug candidate for the treatment of Fragile X Syndrome Anxiety and Behavioral Challenges. The clinical trial was evaluating ZYNE's ZYN002 cannabidiol, a.k.a. CBD gel in pediatric and adolescent patients with Fragile X syndrome.
A quick look at the most recent short interest data and we see that there are over 3 million shares of ZYNE held short which represents over 22% of ZYNE shares outstanding. Take a look at the chart below and the only word that will come to mind is SQUEEZE!
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.
D/M/O
